Signadori Bio
France, Paris
About Signadori Bio
Signadori Bio is a Paris-based preclinical-stage biopharmaceutical company developing an off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumours. Spun out of Gustave Roussy in 2025 by Dr. Jean-Luc Perfettini and Professor Nathalie Chaput in collaboration with Sofinnova Partners, the company is reprogramming innate immune cells directly inside the patient with its lead candidate SiB-2101.
Latest Funding
SeedAnnounced 2026-05-06
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
4 signals · where the capital is going
Expansion of scientific and operational teams.
businesswire.com
Move platform closer to clinical translation per Sofinnova chair statement.
businesswire.com
+2 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to Signadori Bio? You're in the right place.
Knowing they raised is the start. The edge is what's attached to Signadori Bio.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of Signadori Bio, and who are their main competitors?
Sign up free to ask AI about Signadori Bio
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Invivo Partners
Lead investor · Seed
Tech Stack
Cloudflare
HSTS
Cloudflare Bot Management
Key Highlights
AI InsightsRound is a seed extension that brings Signadori Bio's total seed financing to EUR11.1 million, with Taiho Ventures joining as a new strategic backer alongside existing investors Sofinnova Partners and Invivo Partners.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to Signadori Bio
Selling to Signadori Bio? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to Signadori Bio.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.